S&P 500
(0.03%) 5 088.80 points
Dow J
(0.16%) 39 132 points
(-0.28%) 15 997 points
(-0.33%) $76.24
(10.17%) $1.766
(-0.44%) $2 040.40
(0.44%) $23.08
(-0.70%) $903.25
(0.04%) $0.924
(0.13%) $10.55
(0.04%) $0.789
(0.11%) $93.70

Realtime updates for Essex Bio-Technology Ltd [1061.HK]

Exchange: HKSE Sector: Biotechnology Industry: Biotechnology
Last Updated23 Feb 2024 @ 03:08

-5.11% HKD 2.23

Live Chart Being Loaded With Signals

Commentary (23 Feb 2024 @ 03:08):

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally...

Today's Volume 700 000
Average Volume 108 372
Market Cap 1.27B
EPS HKD0 ( 2023-08-16 )
Last Dividend HKD0.0450 ( 2023-08-29 )
Next Dividend HKD0 ( N/A )
P/E 5.07
ATR14 HKD0.0150 (0.67%)

Essex Bio-Technology Ltd Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Essex Bio-Technology Ltd Financials

Annual 2022
Revenue: HKD1.32B
Gross Profit: HKD1.19B (90.26 %)
EPS: HKD0.390
Q2 2023
Revenue: HKD899.36M
Gross Profit: HKD810.46M (90.12 %)
EPS: HKD0.280
Q4 2022
Revenue: HKD661.89M
Gross Profit: HKD602.69M (91.06 %)
EPS: HKD0.140
Q2 2022
Revenue: HKD655.83M
Gross Profit: HKD586.64M (89.45 %)
EPS: HKD0.230

Essex Bio-Technology Ltd Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)

Essex Bio-Technology Ltd Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 1.541 - No dividend expected

Very Unsafe

High risk of being cut


Heightened risk of being cut


Moderate risk of being cut


Unlikely to be cut

Very Safe

Very unlikely to be cut

First Dividend HKD0.0100 2009-04-30
Last Dividend HKD0.0450 2023-08-29
Next Dividend HKD0 N/A
Payout Date 0000-00-00
Next Payout Date
# dividends 21 --
Total Paid Out HKD0.602 --
Avg. Dividend % Per Year 0.00% --
Score 3.71 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 1.541
Div. Directional Score 10.00 --
Next Divdend (Est)
HKD0 Estimate 0.00 %
Dividend Stability
0.07 Very Bad
Dividend Score
Pay Frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
6866.HK Ex Dividend Junior 2023-07-21 Sporadic 0 0.00%
1982.HK No Dividend Player 2023-07-06 Annually 0 0.00%
1066.HK Ex Dividend Knight 2023-10-19 Semi-Annually 0 0.00%
0160.HK No Dividend Player 2023-09-05 Annually 0 0.00%
3360.HK No Dividend Player 2023-06-12 Annually 0 0.00%
1612.HK Ex Dividend Junior 2023-09-05 Annually 0 0.00%
0683.HK Ex Dividend Knight 2023-09-14 Semi-Annually 0 0.00%
9869.HK Ex Dividend Junior 2023-09-19 Insufficient data to determine frequency 0 0.00%
2177.HK No Dividend Player 2023-09-12 Sporadic 0 0.00%
1199.HK Ex Dividend Junior 2023-09-11 Semi-Annually 0 0.00%

Essex Bio-Technology Ltd

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

AboutLive Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators